Biocept, Inc.
BIOCQ
$0.00
$0.000.00%
| Weiss Ratings | BIOCQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | -- | |||
| Risk Index | -- | |||
| Risk Grade | -- | |||
| Reward Grade | -- | |||
| Rating Factors | BIOCQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | -- | |||
| Efficiency Index | -- | |||
| Solvency Index | -- | |||
| Total Return Index | -- | |||
| Volatility Index | -- | |||
| Beta / Standard Deviation | BIOCQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 12,781.71 | |||
| Price History | BIOCQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -100.00% | |||
| 30-Day Total Return | -100.00% | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | -100.00% | |||
| Year to Date Total Return | -100.00% | |||
| 1-Year Total Return | -100.00% | |||
| 2-Year Total Return | -100.00% | |||
| 3-Year Total Return | -100.00% | |||
| 5-Year Total Return | -100.00% | |||
| 52-Week High % Change | -99.98% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | BIOCQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.01 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Mar 11, 2024 | |||
| 52-Week High Price (Date) | Jul 26, 2024 | |||
| Valuation | BIOCQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.00 | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | 0.00 | |||
| Earnings Per Share (TTM) | -50.88 | |||
| Earnings Per Share Growth | 79.96% | |||
| Price/Earnings To Growth | 0.00 | |||
| Price/Sales (TTM) | 0.00 | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BIOCQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.04M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BIOCQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 320 8200 | |||
| Address | 9955 Mesa Rim Road San Diego, CA 92121 | |||
| Website | biocept.com | |||
| Country | United States | |||
| Year Founded | 1997 | |||
| Profitability | BIOCQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -2,445.28% | |||
| Profit Margin | -2,257.22% | |||
| Management Effectiveness | BIOCQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -51.65% | |||
| Return on Equity | -- | |||
| Income Statement | BIOCQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.36M | |||
| Total Revenue (TTM) | 1.36M | |||
| Revenue Per Share | $1.31 | |||
| Gross Profit (TTM) | -14.31M | |||
| EBITDA (TTM) | -31.33M | |||
| EBIT (TTM) | -33.16M | |||
| Net Income (TTM) | -30.61M | |||
| Net Income Avl. to Common (TTM) | -30.61M | |||
| Total Revenue Growth (Q YOY) | -89.88% | |||
| Earnings Growth (Q YOY) | 63.85% | |||
| EPS Diluted (TTM) | -50.88 | |||
| EPS Diluted Growth (Q YOY) | 80.35% | |||
| Balance Sheet | BIOCQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 6.63M | |||
| Cash Per Share (Q) | $6.40 | |||
| Total Current Assets (Q) | 8.86M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 290.00K | |||
| Current Ratio (Q) | 1.807 | |||
| Book Value Per Share (Q) | $0.12 | |||
| Total Assets (Q) | 22.10M | |||
| Total Current Liabilities (Q) | 4.90M | |||
| Total Debt (Q) | 11.59M | |||
| Total Liabilities (Q) | 21.81M | |||
| Total Common Equity (Q) | 290.00K | |||
| Cash Flow | BIOCQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -605.00K | |||
| Cash from Financing (TTM) | 1.91M | |||
| Net Change in Cash (TTM) | -16.30M | |||
| Levered Free Cash Flow (TTM) | -4.24M | |||
| Cash from Operations (TTM) | -17.60M | |||
